$7.55 $0.12 per serving
Product analysis
Hawthorn 358 mg is aimed at heart and blood-vessel support, with a favorable serving cost. The preparation is not established as equivalent to the specific extracts behind the relevant clinical findings.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
A named hawthorn compound does not establish that the preparation matches a specific extract. Different ingredient declarations cannot be combined into a reliable total.
Ingredient Transparency100
The listed amount and preparation details are disclosed, supporting basic label comparisons. Different declarations remain distinct rather than confirming an equivalent active amount.
Value For Money100
The labeled serving offers favorable value. That low serving cost does not establish equivalence to a particular studied extract.
Customer Satisfaction70
Customer ratings are very positive but based on a small number of reviews. That limits confidence about how broadly the reported satisfaction applies.
Product Focus71
The formula focuses on related heart and blood-vessel goals. Findings for specific extracts are conflicting and cannot establish routine benefit for generic hawthorn.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.12
- Customer rating
- 4.7 · 42 ratings
Goals
Impact
High effect
Hawthorn has been studied in heart failure, but the findings are conflicting and concern specific standardized extracts. The saved result recognizes this declared amount, while the supplied context does not establish equivalent benefit from this hawthorn preparation. A general cardiac-tonic effect or prevention of cardiovascular events cannot be described from these facts.
How this product is rated for Heart Health
Ingredient fit81
Hawthorn anchors the recognized ingredient fit; amounts partly meet the saved comparisons.
Goal fit
Hawthorn is central to the recognized heart-health connection, though the product is linked to other goals.
Dose adequacy
The declared amounts partly meet the saved exposure comparisons; this limits recognized contributions without determining clinical effectiveness.
Pathways13
The strongest saved coverage concerns endothelial nitric-oxide function, a limited marker-related connection rather than demonstrated event prevention.
Depth
The strongest saved coverage concerns endothelial nitric-oxide function, a limited marker-related connection rather than demonstrated event prevention.
Breadth
No pathway reaches the saved breadth threshold.
Evidence66
Hawthorn supplies the strongest recognized evidence. Its human findings remain limited to the outcomes and populations described.
Evidence strength
Hawthorn leads the recognized evidence, with the population and outcome limitations described for it.
Studied preparation
The saved findings accept the qualifying preparation; this does not establish delivery or form superiority.
Formulation logic100
No required partner is missing and no configured conflict applies. The recognized ingredients meet the saved minimum amount comparison.
Partner coverage
No required partner is missing for the recognized contributions.
Conflicts
No configured ingredient conflict was found; this does not establish individual suitability.
Effective doses
All recognized ingredients meet the saved minimum amount comparison; this threshold is not proof of clinical effectiveness.
Impact
High effect
Hawthorn · 25 mg
Hawthorn relates to blood-vessel tone in the saved findings, with a partial contribution at 358 mg per serving. The supplied clinical evidence concerns a specific extract in treated heart failure and does not establish routine cardiovascular benefit for generic hawthorn. This declared amount alone does not confirm the studied extract or its composition.
How this product is rated for Cardiovascular Support
Ingredient fit81
The main ingredient or declared actives directly relate to the cardiovascular area represented here.
Goal fit
The main ingredient or declared actives directly relate to the cardiovascular area represented here.
Dose adequacy
The declared amount receives partial recognition relative to the saved amount references; this does not establish a proven response at that exposure.
Pathways41
The findings concentrate on blood-vessel tone.
Depth
The findings concentrate on blood-vessel tone.
Breadth
One area reaches substantial coverage, so the contribution remains focused.
Evidence81
The supplied hawthorn evidence does not transfer automatically to this generic preparation.
Evidence strength
The supplied hawthorn evidence does not transfer automatically to this generic preparation.
Studied preparation
The saved findings recognize the eligible preparation or active declaration; this does not remove the ingredient-specific research limitations.
Formulation logic100
The recognized ingredients have no missing required partner or identified conflict in the supplied checks.
Partner coverage
The recognized ingredients can contribute independently or have their required partner; no additional benefit from combining them is established.
Conflicts
No conflict covered by the supplied checks was identified.
Effective doses
All ingredients retained for this check meet its minimum amount criterion, which is not a proven clinical threshold.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Hawthorn (Crataegus pinnatifida) berry extract (Vitexin-2”-O-Rhamnoside) | 333 mg | |
Hawthorn | 25 mg |
Hawthorn (Vitexin-2”-O-Rhamnoside) · 333 mg OverallScore98
Each serving contains 333 mg of Crataegus pinnatifida berry extract standardized to 1.8%, plus 25 mg of hawthorn. The saved facts do not name the marker used for standardization.
How this ingredient is rated
Composition and Label Disclosure97
The berry extract and second hawthorn ingredient have separate amounts; only the extract has a recorded marker percentage.
Marker and Preparation Disclosure
The 333 mg berry extract is standardized to 1.8%, with the marker unnamed in the saved facts; no marker percentage is recorded for the 25 mg ingredient.
Species Name Disclosure
Crataegus pinnatifida is identified for the berry extract; the species of the other hawthorn ingredient is not identified in the saved facts.
Composition and Label Disclosure
No separate rules were evaluated in this section.
Commercial Price and Usability100
The whole-product serving costs about $0.13, at the lower end of the evaluated serving prices. Different servings may contain different amounts and preparations of hawthorn.
Commercial Price per Labeled Serving
The whole-product serving costs about $0.13, at the lower end of the evaluated serving prices.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Real world effectiveness of Hawthorn special extract WS 1442 in a retrospective cohort study from Germany.
- Hawthorn (Crataegus spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials.
- A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)].
- Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442.
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure].
- Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials.
- Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II.
- Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure--a pooled analysis of clinical trials.